ARRY-334543 + gemcitabine

ARRY-334543 + gemcitabine is a **combination therapy** consisting of ARRY-334543, an oral, reversible, small molecule tyrosine kinase inhibitor targeting ErbB-2 (HER2/neu) and EGFR, and gemcitabine, a nucleoside analog chemotherapeutic agent[1][2][3][5]. ARRY-334543 selectively inhibits ErbB-2 and EGFR signaling pathways, frequently dysregulated in advanced cancers, and has also been shown to antagonize ABCG2-mediated multidrug resistance[2][3]. Gemcitabine is incorporated into DNA and inhibits DNA synthesis, resulting in cytotoxicity in proliferating tumor cells. The combination was investigated in phase 1/2 clinical trials for advanced solid tumors, most notably metastatic pancreatic cancer, with the aim to improve therapeutic efficacy by combining targeted pathway inhibition with cytotoxic chemotherapy[1][5]. The developer of the therapy is Array BioPharma (now a subsidiary of Pfizer)[2][4].

Brand names

ARRY-334543 + gemcitabine

Other names

ARRY-334543 and gemcitabineARRY334543 and gemcitabineARRY 334543 and gemcitabine